Abstract 4992
Background
After a cancer diagnosis, exercise (EX) has shown to reduce risk of recurrence/mortality, help in managing cancer treatment side effects and maintain functional abilities. Nevertheless, most of cancer patients are insufficiently active. The purpose of this research is to investigate the EX level, interest and preference in oncological patients.
Methods
A self-administered questionnaire was used to collect demographic, health and EX information. EX level was assessed by leisure score index (LSI), using the validated Godin’s Leisure Time Exercise Questionnaire, while the EX preferences questions were drawn from previous studies. Patients from Medical Oncology Unit of Verona Hospital were asked to anonymously complete the questionnaire. Descriptive statistic was used to calculate frequencies and percentages of responses to survey questions.
Results
With a 57% of response rate, a total of 405 survey were completed and analyzed. Breast (26%) and upper gastrointestinal (42%) were the most frequent diagnosis. Only 10% of patients resulted to be sufficiently active (LSI≥24). A large majority (80%) indicated that they are willing to participate in an EX program designed for cancer patients. Patients reported that they prefer receive EX information by an oncologist (57%) followed by physiotherapist (29%), with a face to face approach (71%). The preferred composition of EX group was with “other cancer patients” (27%). The patients chose outdoors (27%) and a fitness center for adapted physical activity (21%) as favorite places to perform EX. Training in group was preferred (39%), followed by an individual program to perform at home (27%) and an individual program with a personal trainer (25%). The majority preferred a supervised Ex program (57%). The favorite EX frequencies were two times/week (37%) and three times/week (30%), whereas “mild” intensity was chosen by 44% of patients followed by “moderate” (36%).
Conclusions
Despite the demonstrated benefits of EX in oncological patients, we found 90% of them insufficiently active, but 80% willing to start an EX program. According to these data, we designed a prospective clinical trial including dedicated EX programs based on patient’s preferences, currently recruiting.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of Verona.
Funding
Has not received any funding.
Disclosure
E. Bria: Honoraria (self): MSD, AstraZeneca, Celgene, Pfizer, Helsinn, Eli-Lilly, BMS, Novartis, and Roche; Research grant / Funding (self): AIRC. S. Pilotto: Honoraria (self): AstraZeneca, BMS, Roche, MSD, Boeringher Ingelheim; Research grant / Funding (self): AIRC; Travel / Accommodation / Expenses: BMS, Roche, AstraZeneca, Boehringer Ingelheim. All other authors have declared no conflicts of interest.
Resources from the same session
5141 - Mutational profiling of tumor tissue and sequential plasma illustrates emergent clones during treatment in late stage small cell lung cancer (SCLC)
Presenter: Stephanie Yaung
Session: Poster Display session 1
Resources:
Abstract
5189 - Association between serum HGF levels and neutrophil counts in small cell lung cancer and their impact on survival
Presenter: Laura Moliner
Session: Poster Display session 1
Resources:
Abstract
3539 - Prognostic role of RLF/MYCL1 and circPVT1 in SCLC.
Presenter: Clelia Tiziana Storlazzi
Session: Poster Display session 1
Resources:
Abstract
3438 - High-biologically effective dose radiotherapy improve the survival of small cell lung cancer patients with brain metastases: a propensity-matching analysis
Presenter: Qingyang Zhuang
Session: Poster Display session 1
Resources:
Abstract
3232 - Phase 1 open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABBV-181 and rovalpituzumab tesirine (ROVA-T) in patients with small cell lung cancer
Presenter: Emiliano Calvo
Session: Poster Display session 1
Resources:
Abstract
3633 - Activity of the novel Aurora kinase B inhibitor AZD2811 in biomarker-defined models of small cell lung cancer
Presenter: Carminia Maria Della Corte
Session: Poster Display session 1
Resources:
Abstract
3745 - Multi-level proteomics identifies FABP5 as a primary chemoresistance mediator in extensive-stage small cell lung cancer
Presenter: Yamei Chen
Session: Poster Display session 1
Resources:
Abstract
5049 - CLEPSIDRA trial: a pilot, biomarker-guided study to assess safety, tolerability, dose finding and efficacy of iadademstat in combination with platinum-etoposide in patients with relapsed, extensive-stage small cell lung cancer
Presenter: Alejandro Navarro Mendivil
Session: Poster Display session 1
Resources:
Abstract
5997 - Phased Avelumab combined with chemotherapy as first-line treatment for patients with advanced small-cell lung cancer (SCLC): The PAVE study, a Hellenic Cooperative Oncology Group Study
Presenter: Helena Linardou
Session: Poster Display session 1
Resources:
Abstract
4502 - Tobacco use in lung cáncer (LC) patients (p) in Spain
Presenter: Enric Carcereny Costa
Session: Poster Display session 1
Resources:
Abstract